Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab ravtansine versus vinorelbine in mesothelin-positive advanced malignant pleural mesothelioma
NL-OMON43748Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Feb 2016
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anetumab ravtansine and vinorelbine in pleural mesothelioma, sponsored by Bayer. Primary endpoint: Progression-free survival. Started Feb 2016; status: active, not recruiting.
02
Drugs
anetumab ravtansinevinorelbine
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON43748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43748.